Clinical Support

CKD progression

Studies of plasma biomarkers for CKD progression

READ STUDIES

KidneyIntelX

Studies supporting utility and impact of KidneyIntelX

READ STUDIES
03Aug

KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients

Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients.. Read More →
31Jul

Total Voting Rights

As of 31 July 2020, the Company's issued and fully paid share capital consists of 72,029,634 ordinary shares with a nominal value of £0.0025 each,.. Read More →

Join our
Investor Newsletter

Loading